First HIV rat seen as best model for human studies

August 02, 2001

BALTIMORE, Md.-- With more people living with AIDS than ever before, a new rat model will benefit researchers studying the pathogenesis and the development of new drugs to treat AIDS and related diseases, according to a report in this week's issue of the Proceedings of the National Academy of Sciences.

Scientists at the University of Maryland Biotechnology Institute (UMBI) have engineered laboratory rats for the first time to contain the genome of the AIDS virus HIV-1 except for two genes that make the virus non-infectious. The model cannot transmit the disease to humans.

"The new HIV transgenic rat is an excellent model for studying early and chronic infections, that is, the tracking of the clinical, cellular, and immunologic course of HIV-1 in humans," quotes senior author of a PNAS paper, Joseph L. Bryant, head, Animal Model Division of UMBI's Institute of Human Virology. "It will be especially effective in testing potential therapeutic strategies against chronic AIDS-associated conditions or syndrome."

Now that HIV anti-retroviral therapy can control the virus, giving longer life to AIDS patients, more of them develop diseases of the kidneys, heart, pancreas, skin, and other organs and especially neurological conditions associated with AIDS, explains Bryant.

"The HIV rat model can now tell us a lot about how these patients develop the diseases. If you understand how the HIV genes are causing these problems in particular organs, researchers can learn how, for example, kidney disease develops in AIDS patients, and they can better learn how to treat it in association with other conditions of the syndrome."

By five to nine months of age, the HIV-1 transgenic rats develop clinical signs similar to those of AIDS in humans, including cataracts, weight loss, skeletal muscle atrophy or "wasting," neurological abnormalities, and respiratory difficulty.

Many of the rats also suffered from mild-to-severe skin lesions, kidney disease, and cardiac disorders, all of which have been reported in chronically HIV-infected humans.

Investigations of human immunodeficiency virus (HIV) infection of man have benefited from the study of relevant animal models of the infection and disease, however, the ultimate models use primate species, which are either endangered, not generally available, or expensive to maintain, states Dr. J. C. Hunter-Cevera, president of UMBI. "We are very excited about the new potential studies with the IHV transgenic rat model that Dr. Bryant and his team at IHV have developed."

In addition, the HIV rats are also more efficient than mouse models for blood and tissue specimens. Mice provide only 2 to 3 millimeters of blood, rats 30 to 40 millimeters. Organ studies are also easier with the larger animals.

While HIV transgenic mice produce the highest levels of viral proteins in skin and muscle, according to lead author William Reid, IHV assistant professor, the HIV-gene carrying rats produce viral proteins and RNA in a variety of lymphoid tissues, including lymph nodes, spleen, thymus, and blood. The rats also display cellular and immune irregularities characteristics of HIV-1 infection.
The University of Maryland Biotechnology Institute was mandated by the state of Maryland legislature in 1985 as "a new paradigm of state economic development in biotech-related sciences." With five major research and education centers across Maryland, UMBI is dedicated to advancing the frontiers of biotechnology. The centers are the Center for Advanced Research in Biotechnology in Rockville; Center for Agricultural Biotechnology in College Park; and Center of Marine Biotechnology, Medical Biotechnology Center, and the Institute of Human Virology, all in Baltimore.

University of Maryland Biotechnology Institute

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to